Lv11
36 积分 2024-09-09 加入
Lessons from recent clinical trials for the prevention of acute pancreatitis in chylomicronemia syndromes
53分钟前
求助中
Tirzepatide: First Approval
9天前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
10天前
已完结
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
10天前
已完结
A randomized, placebo‐controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers
1个月前
已完结
Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes
1个月前
已完结
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
1个月前
已完结
Kardiovaskuläre Auswirkungen einer Liraglutidtherapie bei Patienten mit Typ-2-Diabetes
1个月前
已完结
Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
3个月前
已完结
Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants
3个月前
已完结
皖公网安备34019202002308
